{Reference Type}: Journal Article
{Title}: Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
{Author}: Yoshinami T;Nozawa K;Yokoe T;Ozaki Y;Nishio H;Tsuchihashi K;Ichihara E;Miura Y;Endo M;Yano S;Maruyama D;Susumu N;Takekuma M;Motohashi T;Ito M;Baba E;Ochi N;Kubo T;Uchino K;Kimura T;Kamiyama Y;Nakao S;Tamura S;Nishimoto H;Kato Y;Sato A;Takano T;
{Journal}: Int J Clin Oncol
{Volume}: 29
{Issue}: 6
{Year}: 2024 Jun 23
{Factor}: 3.85
{DOI}: 10.1007/s10147-024-02504-4
{Abstract}: <B>BACKGROUND: </B>Granulocyte colony-stimulating factor (G-CSF) is widely used for the primary prophylaxis of febrile neutropenia (FN). Two types of G-CSF are available in Japan, namely G-CSF chemically bound to polyethylene glycol (PEG G-CSF), which provides long-lasting effects with a single dose, and non-polyethylene glycol-bound G-CSF (non-PEG G-CSF), which must be sequentially administrated for several days.<BR><B>METHODS: </B>This current study investigated the utility of these treatments for the primary prophylaxis of FN through a systematic review of the literature. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis or meta-analysis was conducted to evaluate six outcomes.<BR><B>RESULTS: </B>Through the first and second screenings, 23 and 18 articles were extracted for qualitative synthesis and meta-analysis, respectively. The incidence of FN was significantly lower in the PEG G-CSF group than in the non-PEG G-CSF group with a strong quality/certainty of evidence. The differences in other outcomes, such as overall survival, infection-related mortality, the duration of neutropenia (less than 500/μL), quality of life, and pain, were not apparent.<BR><B>CONCLUSIONS: </B>A single dose of PEG G-CSF is strongly recommended over multiple-dose non-PEG G-CSF therapy for the primary prophylaxis of FN.